News
NeurAxis Highlights Pediatric Post-Concussion Clinical Study
CARMEL, Ind., Aug. 29, 2023 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted A...
NeurAxis Highlights Strength of its Board of Directors
CARMEL, Ind., Aug. 24, 2023 -- NeurAxis, Inc. (NYSE American: NRXS), ("NeurAxis," or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the...
NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome
CARMEL, Ind., Aug. 22, 2023 -- NeurAxis, Inc. (NYSE American: NRXS), ("NeurAxis," or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlights two...
NeurAxis Announces Over $8 Million in IB-Stim™ Revenue
CARMEL, Ind., Aug. 17, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced it has...
NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023
CARMEL, Ind., Aug. 15, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced a poster...
NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin
CARMEL, Ind., Aug. 10, 2023 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted...
NeurAxis Announces Pricing of Initial Public Offering
CARMEL, Ind., Aug. 09, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the...